Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | RHOC | P08134 | 1/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094229 | 1.00 | KDR (0.51) | KDRPSMB8SMN1; SMN2MAPTULK1 | |
| SCHEMBL20094557 | 1.00 | KDR (0.51) | KDRPSMB8SMN1; SMN2MAPTULK1 | |
| SCHEMBL20088373 | 0.91 | KDR (0.47) | KDRPSMB8SMN1; SMN2MAPTULK1 | |
| SCHEMBL20088371 | 0.91 | KDR (0.47) | KDRPSMB8SMN1; SMN2MAPTULK1 | |
| SCHEMBL21580333 | 0.86 | SCN3A (0.52) | KDRPSMB8ULK1SCN3ASCN9A | |
| SCHEMBL4282333 | 0.81 | HTR1A (0.43) | KDRSMN1; SMN2HTR2CLMNATERT | |
| SCHEMBL4274244 | 0.81 | HTR1A (0.43) | KDRSMN1; SMN2HTR2CLMNATERT | |
| SCHEMBL4270711 | 0.81 | HTR1A (0.43) | KDRSMN1; SMN2HTR2CLMNATERT | |
| SCHEMBL4270706 | 0.81 | HTR1A (0.43) | KDRSMN1; SMN2HTR2CLMNATERT | |
| SCHEMBL4274250 | 0.81 | HTR1A (0.43) | KDRSMN1; SMN2HTR2CLMNATERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | KDR 4653/4885PSMB8 3868/4885SMN1; SMN2 307/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | KDR 4653/4885PSMB8 3868/4885SMN1; SMN2 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.